Adenosine receptors in neurological disorders

Bibliography

• OLAH M, STILES GL: The role of receptor structure in determining adenosine receptor activity. Pharmacol. Ther. (2000) 85:55–75.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of the structure and function ofadenosine receptors.
   Google Scholar
• ONGINI E, SCHUBERT P: Neuroprotection induced by stimulating Ai or blocking A2Aadenosine receptors: an apparent paradox. Drug Dev. Res. (1998) 45:387–393.
   Google Scholar
• WEISNER J, UGARKAR BG, CASTELLINO AJ et al.: Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy. J. Pharmacol. Exp. Ther. (1999) 289:1669–1677.
   Google Scholar
• ADAMI M, BERTORELLI R, FERRI N, FODDI MC, ONGINI E: Effects of repeated administration of selective adenosine Ai and A2A receptor agonists on pentylenetetrazole-induced convulsions in the rat. Eur.J. Pharmacol. (1995) 294:383–389.
   PubMed Web of Science ®Google Scholar
• SAWYNOK J: Adenosine receptor activation and nociception. Eur.J. Pharmacol (1998) 317:1–11.
   Google Scholar
• SATOH S, MATSUMARA H, KOIKE N, TOKUNAGA Y, MAEDA T, HAYAISHI O, Region-dependent difference in the sleep-promoting potency of an adenosine A2A receptor agonist. Eur.J. Neurosci. (1999) 11:1587–1597.
   PubMed Web of Science ®Google Scholar
• ONGINI E, FREDHOLM BB: Pharmacology of adenosineA2A receptors. Trends Pharmacol. ScL (1996) 17:364–372.
   PubMed Web of Science ®Google Scholar
• RICHARSON PJ, KASE H, JENNER PG: Adenosine A2Areceptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol. ScL (1997) 18:338–344.
   Google Scholar
• LEDENT C, VAUGEOIS JM, SCHIFFMANN SN, PEDRAZZINI T et al: Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2A receptor. Nature (1997) 388:674–678.
   PubMed Web of Science ®Google Scholar
• ••First description of A2A knockout mice.
   Google Scholar
• CHEN JF, HUANG Z, MA J et al.: A2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci. (1999) 19:9192–9200.
   PubMed Web of Science ®Google Scholar
• SALVATORE CA, TILLEY SL, LATOUR AM, FLETCHER DS, KOLLER BH, JACOBSON MA: Disruption of the A3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol. Chem. (2000) 275:4429–4434.
   PubMed Web of Science ®Google Scholar
• JOHANSSON B, FREDHOLM BB, HEERLENIUS E et al.: Altered synaptic transmission, reduced hypoxia response and hyperalgesia in adenosine Ai knockout mice. 30th Annual Meeting Society of Neuroscience. New Orleans, Louisiana, USA (2000).
   Google Scholar
• ••This abstract is the first report on A1 knockout mice.
   Google Scholar
• MATHERNE GP, LINDEN J, BYFORD AM, GAUTHIER NS, HEADRICK JP: Transgenic Ai adenosine receptor overexpression increases myocardial resistance to ischemia. Proc. Nati Acad. Sof. USA (1997) 94:6541–6546.
   PubMedGoogle Scholar
• CALABRESI P, CENTONZE D, PISANI A, BERNARDI G:Endogenous adenosine mediates the presynaptic inhibition induced by aglycemia at corticostriatal synapses. J Neurosci. (1997) 17:4509–4516.
   Google Scholar
• FERRE' S, FREDHOLM BB, MORELLI M, POPOLI P, FUXE K:Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. (1997) 20:482–487.
   Google Scholar
• •An excellent review of A2A/D2 receptor interaction.
   Google Scholar
• DIXON AK, GUBITZ AK, SIRINATHSINGHJI DJS, RICHARDSON PJ, FREEMAN TC: Tissue distribution of adenosine receptor mRNAs in the rat. Br. J. Pharmacol (1996) 118:1461–1468.
   PubMed Web of Science ®Google Scholar
• SVENNINGSSON P, HALL H, SEDVALL G, FREDHOLM BB: Distribution of adenosine receptors in the post-mortem human brain. An extended autoradio-graphic study. Synapse (1997) 27:322–335.
   PubMed Web of Science ®Google Scholar
• GILCHRIST A, MAZZONI MR, DINEEN B et al: Antagonists of receptor-G protein interface block Gi-coupled signal transduction. J Biol. Chem. (1998) 273 :14912–14919.
   PubMed Web of Science ®Google Scholar
• MET YA, LE FOLL F, VAUDRY H, CAZIN L: Adenosineinhibits L-and N-type calcium channels in pituitary melanotrophs. Evidence for the involvement of a G protein in calcium channel gating. J. Neuroendocrinol. (1996) 8:85–91.
   Google Scholar
• BIBER K, KLOTZ KN, BERGER M, GEBICKE-HERBER PJ, VAN CALKER D: Adenosine Ai receptor-mediated activation of phospholipase C in cultured astrocytes depends on the level of receptor expression. J. Neurosci. (1997) 17 (13):4956–4964.
   Google Scholar
• AKBAR M, OKAJIMA F, TOMURA H, SHIMEGI S, KONDO, Y: A single species of Ai adenosine receptor expressed in Chinese hamster ovary cells not only inhibits cAMP accumulation but also stimulates phospholipase C and arachidonate release. Mol. Pharmacol. (1994) 45:1036–1042.
   PubMed Web of Science ®Google Scholar
• JACOBSON KA, VAN GALEN PJM, WILLIAMS M: Adenosine receptors: pharmacology, structure-activity relationship and therapeutic potential. J. Med. Chem. (1992) 35:407–422.
   PubMed Web of Science ®Google Scholar
• KLOTZ KN, HESSLING J, HEGLER J et al: Comparativepharmacology of human adenosine receptor subtype-characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch. Pharmacol. (1998) 357:1–9.
   Google Scholar
• ZOCCHI C, ONGINI E, FERRARA S, BARALDI PG, DIONISOTTI S: Binding of the radioligand [311]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes. Br. J Pharmacol. (1996) 117:1381–1386.
   PubMed Web of Science ®Google Scholar
• DIONISOTTI S, ONGINI E, ZOCCHI C, KULL B, ARSLAN G, FREDHOLM BB: Characterization of human A2A adenosine receptors with the antagonist radioligand [311]-SCH 58261. Br. J. Pharmacol (1997) 121 :353–360.
   PubMedGoogle Scholar
• SALVATORE CA, JACOBSON MA, TAYLOR HE, LINDEN J, JOHNSON RG: Molecular cloning and characterization of the human A3 adenosine receptor. Proc. Natl. Acad. Sci. USA (1993) 90:10365–10369.
   PubMed Web of Science ®Google Scholar
• VARANI K, CACCIARI B, BARALDI PG, DIONISOTTI S, ONGINI E, BOREA PA: Binding affinity of adenosine receptor agonists and antagonists at human cloned A3 adenosine receptors. Life Sci. (1998) 63:81–87.
   Web of Science ®Google Scholar
• VARANI K, MERIGHI S, GESSI S et al: pflPIRE3008F20: A novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. Mol. Pharmacol. (2000) 57:968–975.
   PubMed Web of Science ®Google Scholar
• SHIMADA J, KOIKE N, NONAKA H et al.: Adenosine A2A antagonist with potent anticataleptic activity. Bioorg. Med. Chem. (1997) 7:2349–2352.
   Google Scholar
• MARSTON HM, FINLAYSON K, MAEMOTO T et al.: Pharmacological characterization of a simple behavioural response mediated selectively by central adenosine A1 receptors, using in vivo and in vitro techniques. J. Pharmacol. Exp. Ther. (1998) 285:1023–1030.
   Google Scholar
• EL YACOUBI M, LEDENT C, MENARD JF, PARMENTIER M, COSTENTIN J, VAUGEOIS JM: The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A2A receptors. Br. J. Pharmacol. (2000) 129:1465–1473.
   PubMed Web of Science ®Google Scholar
• FLORIO C, ROSATI AM, TRAVERSA U, VERTUA R: Inhibi-tory and excitatory effects of adenosine antagonists on spontaneous locomotor activity in mice. Life Sci. (1997) 60:1477–1486.
   Google Scholar
• COMMISSARIS RL, MCCLOSKEY TC, DAMIAN GM, BROWN BD, BARRACO RA, ALTMAN HJ: Antagonism of the anti-conflict effects of phenobarbital, but not diazepam, by the Ai adenosine agonist L-PIA. Psycho-pharmacology (1990) 102:283–290.
   Web of Science ®Google Scholar
• JAIN N, KEMP N, ADEYEMO O, BUCHANAN P, STONE TVV: Anxiolytic activity of adenosine receptor activation in mice. Br. J. Pharmacol. (1995) 116:2127–2133.
   PubMed Web of Science ®Google Scholar
• FLORIO C, PREZIOSO A, PAPAIOANNOU A, VERTUA R: Adenosine A1 receptors modulate anxiety in CD1 mice. Psychopharmacology (1998) 136:311–319.
   Google Scholar
• HARAGUCHI H, KURIBARA H: Behavioural effects ofadenosine agonists: evaluation by punishment, discrete shuttle avoidance and activity tests in mice. Jpn. Pharmacol. (1991) 55:303–310.
   Google Scholar
• KUROKAWA M, KOGA K, KASE H, NAKAMYRA J, KUWANA Y: Adenosine A2Areceptor-mediated modula-tion of striatal acetylcholine release in vivo. J. Neurochem. (1996) 66:1882–1888.
   Google Scholar
• CONSTENLA AR, DE MENDONCA A, RIBEIRO JA: Adenosine modulates synaptic plasticity in hippocampus slices from aged rats. Brain Res. (1999) 851:228–234.
   Google Scholar
• KEMP N, BASHIR ZI: A role for adenosine in the regula-tion of long-term depression in the adult rat hippocampus in vitro. Neurosci. Lett. (1997) 225:189–192
   PubMedGoogle Scholar
• VON LUBITZ DKJE, PAUL IA, CARTER MF, JACOBSON KA: Effects of N6-cyclopentyladenosine and 8-cyclop en tyl-1, 3-dipropylx anthin eonN-methyl-D-aspartate induced seizures in mice. Eur. Pharmacol. (1993) 249:265–270.
   Google Scholar
• SUZUKI F, SHIMADA J, SHIOZAKI S et al.: Adenosine Ai antagonists. 3. Structure-activity relationships on amelioration against scopolamine-or N6-0)-phenyl-isopropyliadenosine-induced cognitive disturbance. J Med. Chem. (1993) 36:2508–2518.
   Google Scholar
• ZHANG G, FRANKLIN PH, MURRAY TF: Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizure susceptibility. J. Pharmacol. Exp. Ther. (1993) 264:1415–1424.
   PubMed Web of Science ®Google Scholar
• YOUNG D, DRAGUNOW M: Status epilepticus may be caused by loss of adenosine anticonvulsant mechanism. Neuroscience (1994) 58:245–261.
   PubMed Web of Science ®Google Scholar
• PAGONOPOULOU O, ANGELATOU F: Time develop-ment and regional distribution of rilinitrobenzyl-thioinosine adenosine uptake site binding in the mouse brain after acute pentylenetetrazol-induced seizures. J. Neurosci. Res. (1998) 53:433–442.
   Google Scholar
• DE SARRO GB, DE SARRO A, DONATO DI PAOLA E, BERTORELLI R: Effects of adenosine receptor agonists and antagonists on audiogenic seizure-sensible DBA/2 mice. Eur.j Pharmacol. (1999) 371:137–145.
   PubMed Web of Science ®Google Scholar
• EKONOMOU A, SPERK G, KOSTOPOULOS G, ANGELATOU F: Reduction of Ai adenosine receptors in rat hippocampus after kainic-acid induced limbic seizures. Neurosci. Lett. (2000) 284:49–52.
   Google Scholar
• RUDOLPHI KA, SCHUBERT P, PARKINSON FE, FREDHOLM BB: Neuroprotective role of adenosine in cerebral ischemia. Trends Pharmacol Sci. (1992) 13:439–445.
   PubMed Web of Science ®Google Scholar
• LOGAN M, SWEENEY ML: Adenosine Ai receptor activa-tion preferentially protects cultured cerebellar neurons astrocytes against hypoxia-induced death. Mol. Chem. Neuropathol. (1997) 31:119–133.
   Google Scholar
• VON LUBITZ DK: Adenosine and cerebral ischaemia:therapeutic future or death of a brave concept? Eur. Pharmacol. (1999) 371:85–102.
   Google Scholar
• VON LUBITZ DKJE, DAMBROSIA JM, REDMON DJ: Protec-tive effect of cyclohexyl adenosine in treatment of cerebral ischemia in gerbils. Neuroscience (1989) 2:451–457.
   Google Scholar
• PHILLIS JW: The effects of selective Ai and A2 adenosinereceptor antagonists on cerebral ischaemic injury in the gerbil. Brain Res. (1995) 705:79–84.
   PubMed Web of Science ®Google Scholar
• BONA E, ADEN U, GILLAND E, FREDHOLM BB, HAGBERGH: Neonatal cerebral hypoxia-ischemia: the effect of adenosine receptor antagonists. Neuropharmacology (1997) 36 1327–1338.
   PubMed Web of Science ®Google Scholar
• ARVIN B, NEVILLE NF, PAN J, ROBERTS PJ: 2-Chloroadeno sine attenuates kainic acid induced toxicity within the rat striatum: relationship to release of glutamate and calcium influx. Br. J. Pharmacol (1989) 98:225–253.
   PubMed Web of Science ®Google Scholar
• MACGREGOR DG, MILLER DW, STONE TVV: Mediation ofneuroprotective action of R-phenylisopropyladen-osine through a centrally located adenosine Ai receptor. Br. J. Pharmacol. (1993) 110:470–476.
   PubMed Web of Science ®Google Scholar
• KOWALUK EA, KOHLHAAS KL, BANNON A, GUNTHER K, LYNCH JJ, JARVIS MF: Characterization of the effects of adenosine kinase inhibitors on acute thermal nocicep-tion in mice. Pharmacol Biochem. Behav. (1999) 63:83–91.
   PubMed Web of Science ®Google Scholar
• CUI JG, SOLLEVI A, LINDEROTH B, MEYERSON BA: Adenosine receptor activation suppresses tactile hypersensitivity and potentiates spinal cord stimula-tion in mononeuropathic rats. Neurosci. Lett. (1997) 223 173–176.
   PubMed Web of Science ®Google Scholar
• VON HEIJNE M, HAO JX, SOLLEVI A, XU XJ: Intrathecaladenosine does not relieve allodynia-like behavior in spinally injured rats. NeuroReport (1999) 1 0:3247–3251.
   Google Scholar
• SEGERDAHL M, EKBLOM A, SIOLUND KF, BELFRAGE M, FORSBERG C, SOLLEVI A: Systemic adenosine attenu-ates touch evoked allodynia induced by mustard oil in humans. NeuroReport (1995) 6:753–756.
   PubMed Web of Science ®Google Scholar
• KOWALUK EA, YU H, MIKUSA J et al.: ABT-702, a novelorally effective adenosine kinase (AK) inhibitor analgesic with antiinflammatory properties. Drug Dev. Res. (2000) 50:104.
   Google Scholar
• LEE C, JIANG M, BHAGWAT S et al: Structure-activity relationship of a series of novel, non-nucleoside analogs as adenosine kinase inhibitors. Drug Dev. Res. (2000) 50:62.
   Google Scholar
• LEE YW, YAKSH TL: Pharmacology of the spinal adenosine receptor which mediates the antiallodynic action of intrathecal adenosine agonists. j Pharmacol Exp. Ther. (1996) 277:1642–1648.
   PubMed Web of Science ®Google Scholar
• LINDSAY EA, MORRIS MA, GOS A et al: Schizophrenia and chromosomal deletions within 22q11.2. Am. J Hum. Genet. (1995) 56:1502–1503.
   PubMed Web of Science ®Google Scholar
• PALMER TM, JACOBSON KA, STILES GL: Immunological identification of A2 adenosine receptors by two an tip ep tide antibody preparations. Mol. Pharmacol (1992) 42: 391–397.
   Google Scholar
• RIBEIRO JA: Adenosine A2A receptor interactions with receptors for other neurotransmitters and neuromodulators. Eur.J. Pharmacol (1999)375:101–113.
   PubMed Web of Science ®Google Scholar
• ASKALAN R, RICHARDSON PJ: Role of histidine residuesin the adenosine A2A receptor ligand binding site. J Neurochem. (1994) 63:1477–1484.
   Google Scholar
• JOHANSSON B, FREDHOLM BB: Further characteriza-tion of the binding of the adenosine receptor agonist, [3H]CGS 21680 to rat brain using autoradiography. Neuropharmacology (1995) 34:393–403.
   Google Scholar
• ROSIN DL, ROBEVA A, WOODARD RL, GUYENET PG, LINDEN J: Immunohisto chemical localization of adenosine A2A receptors in the rat central nervous system. J. Comp. Neurol (1998) 401:163–186.
   PubMed Web of Science ®Google Scholar
• SVENNINGSSON P, LE MOINE C, FISONE G, FREDHOLM BB: Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol (1999) 59:355–396.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of A2A receptors.
   Google Scholar
• FINK JS, WEAVER DR, RIVKEES SA et al: Molecular cloning of the rat A2A adenosine receptor; selective co-expression with D2 dopamine receptors in rat striatum. Mol Brain Res. (1992) 14:186–195.
   PubMedGoogle Scholar
• SVENNINGSSON P, LE MOINE C, KULL B, SUNAHARA R, BLOCH B, FREDHOLM BB: Cellular expression of adenosine A2A receptor mRNA in the rat central nervous system with special reference to dopamine innervated areas. Neuroscience (1997) 80:1171–1185.
   PubMed Web of Science ®Google Scholar
• SONG WJ, TKATCH T, SURMEIER DJ: Adenosine receptor expression and modulation of Ca2+ channels in rat striatal cholinergic interneurons. j Neurophysiol. (2000) 83:322–332.
   PubMed Web of Science ®Google Scholar
• PRESTON Z, LEE K, WIDDOWSON L, FREEMAN TC, DIXON AK, RICHARDSON PJ: Adenosine receptor expression and function in rat striatal cholinergic interneurons. Br. J Pharmacol (2000) 130(4):886–90.
   Google Scholar
• CUNHA RA, COSTANTINO MD, RIBEIRO JA: G proteincoupling of CGS 21680 binding sites in the rat hippocampus and cortex is different from that adenosine Ai and striatal A2A receptors. Naunyn-Schmiedberg's Arch. Pharmacol. (1999) 51:199–206.
   Google Scholar
• KAELIN-LANG A, LAUTERBURG T, BURGUNDER JM: Expression of adenosine A2A receptors gene in the olfactory bulb and spinal cord of rat and mouse. Neurosci. Lett. (1999) 261:189–191.
   Google Scholar
• WEAVER DR: A2A adenosine receptor gene expressionin developing rat brain. Brain Res. Mol. Brain Res. (1993) 20:313–327.
   PubMedGoogle Scholar
• JOHANSSON B, GEORGIEV V, FREDHOLM BB: Distribu-tion and postnatal ontogeny of adenosine A2A receptors in rat brain: comparison with dopamine receptors. Neuroscience (1997) 80:1187–1207.
   Google Scholar
• ARSLAN G, KULL B, FREDHOLM BB: Signaling via A2A adenosine receptors in four PC 12 cell clones. Naunyn-Schmiedeberg's Arch. Pharmacol. (1999) 359:28–32.
   Google Scholar
• LINDSKOG M, SVENNINGSSON P, FREDHOLM BB, GREENGARD P, FISONE G: Activation of dopamine D2 receptor decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neuron via different mechanism. Neuroscience (1999) 88:1005–1008.
   Google Scholar
• FIENBERG AA, GREENGARD P: The DARPP-32 knockout mouse. Brain Res. Brain Res. Rev. (2000) 31:313–319.
   PubMedGoogle Scholar
• BIBB JA, SNYDER GL, NISHI A et al: Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature (1999) 402:669–671.
   PubMed Web of Science ®Google Scholar
• GONCALVES ML, CUNHA RA, RIBEIRO JA: Adenosine A2A receptors facilitate 45 Ca2+ uptake through class A calcium channels in rat hippocamp al CA3 but not CA1 synaptosomes. Neurosci. Lett. (1997) 238:73–77.
   PubMed Web of Science ®Google Scholar
• GUBIYZ AK, WIDDOWSON L, KUROKAWA M, KIRKPATRICK KA, RICHARDSON PJ: Dual signalling by the adenosine A2A receptor involves activation of both N-and P-type calcium channels by different G proteins and protein kinases in the same striatal nerve terminals. J. Neurochem. (1996) 67:374–381.
   Google Scholar
• DIXON AK, WIDDOWSON L, RICHARDSON PJ: Desensiti-zation of adenosine Ai receptor by the A2A receptor in the rat striatum. J. Neurochem. (1997) 69:315–321.
   PubMed Web of Science ®Google Scholar
• FUXE K, FERRE' S, ZOLI M, AGNATI L: Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine Ai/dopamine Di receptor interactions in the basal ganglia. Brain Res. Rev. (1998) 26:258–273.
   PubMedGoogle Scholar
• ••A comprehensive review of A1 and A2A receptor function.
   Google Scholar
• JIN S, JOHANSSON B, FREDHOLM BB: Effects of adenosine Ai and A2A receptor activation on electri-cally evoked dopamine and acetylcholine release from rat striatal slices. J. Pharmacol. Exp. Ther. (1993) 267:801–808.
   Google Scholar
• SVENNINGSSON P, NERGARDH R, FREDHOLM BB: Regional differences in the ability of caffeine to affect haloperidol-induced striatal c-fos mRNA expression in the rat. Neuropharmacology (1998) 37:331–337.
   Google Scholar
• KULL B, ARSLAN G, NILSSON C, LORENZON A, SCHVVABEU, FREDHOLM BB: Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. Biochem. Pharmacol (1999) VOL 57:65–75.
   Google Scholar
• KULL B, FERRE' S, ARLSAN G et al: Reciprocal interac-tions between adenosine A2A and dopamine D2 receptors co-transfected in CHO cells. Biochem. Pharmacol. (1999) 58:1035–1045.
   PubMed Web of Science ®Google Scholar
• SALIM H, FERRE' S, DALAL A et al.: Activation of adenosine Ai and A2A receptors modulates dopamine D2 receptor-induced responses in stably transfected human neuroblastoma cells. J. Neurochem. (2000) 74:432–439.
   Google Scholar
• SVENNINGSSON P, LINDSKOG M, LEDENT C et al: Regulation of the phosphorylation of the dopamine and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine Di, dopamine D2 and adenosine A2A receptors. Proc. Natl. Acad. Sci. USA (2000) 97:1856–1860.
   PubMed Web of Science ®Google Scholar
• ••This original paper describes the effects of A2A receptorinactivation on DARPP-32 protein.
   Google Scholar
• ONGINI E, DIONISOTTI S, GESSI S, IRENIUS E, FREDHOLM BB: Comparison of CG515943, ZM241385 and SCH 58261 as antagonists at human adenosine receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. (1999) 359:7–10.
   Google Scholar
• RALEVIC V, BURNSTOCK G: Receptors for purine and pyrimidines. Pharmacol. Rev. (1998) 50:413–492.
   PubMed Web of Science ®Google Scholar
• FREDHOLM BB, BATTIG K, HOLMEN J, NEHLIG A, ZVARTAU EE: Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. (1999) 51:83–133.
   PubMed Web of Science ®Google Scholar
• •An overview of the functions of the most widely used A2A receptor antagonist, caffeine.
   Google Scholar
• MONOPOLI A, CONTI A, ZOCCHI C et al.: Pharmacology of the new selective A2A adenosine receptor agonist 2-h exyny1-5 '-N-ethylcarbox amidoadeno sine. Arzneimittel-Forschung/Drug Res. (1994) 44:1296–1304.
   PubMed Web of Science ®Google Scholar
• POUCHER SM, KEDDIE JR, SINGH P et al.: The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2A selective adenosine receptor antagonist. Br. J Pharmacol. (1995) 115:1096–1102.
   PubMed Web of Science ®Google Scholar
• TURGEON SM, POLLACK AE, SCHUSHEIM L, FINK JS: Effects of selective Ai and A2A agonists on amphetamine-induced locomotion and c-fos in striatum and nucleus accumbens. Brain Res. (1996) 707:75–80.
   Google Scholar
• EL YACOUBI M, LEDENT C, PARMENTIER M, COSTENTIN J, VAUGEOIS J: SCH58261 and ZM 241385 differentially prevent the motor effects of CGS 21680 in mice: evidence for a functional 'atypical' adenosine A(2A) receptor. Eur. j Pharmacol. (2000) 401:63–67.
   Google Scholar
• MANDHANE SN, CHOPDE CT, GHOSH AK: Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats. Eur.j Pharmacol (1997) 328:135–141.
   Google Scholar
• MORELLI M, FENU S, PINNA A, DI CHIARA G: Adenosine A2A receptors interact negatively with dopamine Di and D2 receptors in unilaterally 6-hydroxydop amine-lesioned rats. Eur. j Pharmacol. (1994) 251:21–25.
   Google Scholar
• GRONDIN R, BEDARD PJ, HADJ TAHAR A, GREGOIRE L, MORI A, KASE H: Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology (1999) 52:1673–1677.
   PubMed Web of Science ®Google Scholar
• ••This and [101] document the effects of a promising A2Areceptor antagonist in non-human primates.
   Google Scholar
• KANDA T, JACKSON MJ, SMITH LA et al: Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian models. Ann. Neurol (1998) 43:507–513.
   PubMed Web of Science ®Google Scholar
• ••See annotation for [100].
   Google Scholar
• ROBERTSON GS, TETZLAFF W, BEDARD A, ST-JEAN M, WIGLE N: c-fos mediated antipsychotic-induced neurotensin gene expression in rodent striatum. Neuroscience (1995) 67:325–344.
   Google Scholar
• MARTIN GE, ROSSI DJ, JARVIS MF: Adenosine agonist reduced conditioned avoidance responding in the rat. Pharmacol. Biochem. Behav. (1993) 45:951–958.
   Google Scholar
• KAFKA SH, CORBETT R: Selective A2A receptor/dopamine D2 receptor interactions in animal models of schizophrenia. Eur. J. Pharmacol. (1996) 295:263–268.
   Google Scholar
• HAUBER W, KOCH M: Adenosine A2A receptors in the nucleus accumbens modulate prepulse inhibition of the startle response. NeuroReport (1997) 8:1515–1518.
   Google Scholar
• MORELLI M, PINNA A, WARDAS J, DI CHIARA G: Adenosine A2 receptors stimulate c-fos expression in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience (1995) 67:49–55.
   Google Scholar
• KOOB GF, LE MOAL M: Drug abuse: hedonic homeostatic dysregulation. Science (1997) 278:52–58.
   PubMed Web of Science ®Google Scholar
• FIORINO DF, PHILLIPS AG: Facilitation of sexual behaviour in male rats following D-amphetamine--induced behavioural sensitization. Psychopharma-cology (1999) 142:200–208.
   Google Scholar
• SELF DW, NESTLER EJ: Molecular mechanisms of drug reinforcement and addiction. Ann. Rev. Neurosci. (1995) 18:463–495.
   PubMed Web of Science ®Google Scholar
• NIKODIJEVIC O, JACOBSON KA: Locomotor activity in mice during chronic treatment with caffeine and withdrawal. Pharmacol. Biochem. Behav. (1993) 44:199–216.
   Google Scholar
• RIMONDINI R, FERRE' S, GIMENEZ-LLORT L, OGREN SO, FUXE K: Differential effects of adenosine Ai and A2 receptor agonists on dopamine receptor agonist-induced behavioural responses in rats. Eur. J. Pharmacol. (1998) 347:153–158.
   PubMed Web of Science ®Google Scholar
• CHEN JF, BEILSTEIN M, TURNER TJ et al.: Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A2A adenosine receptors. Neuroscience (2000) 97:195–204.
   PubMed Web of Science ®Google Scholar
• ••An interesting paper that points out the potentials of A2Areceptor antagonists in drug addiction.
   Google Scholar
• SAHRAEI H, MOTAMEDI F, KHOSHBATEN A, ZARRIN-DAST MR: Adenosine A2 receptors inhibit morphine self-administration in rats. Eur. j Pharmacol. (1999) 383:107–113.
   Google Scholar
• BALDO BA, KOOB GF, MARKOU A: Role of adenosine A2 receptors in brain stimulation reward under baseline conditions and during cocaine withdrawal in rats. J Neurosci. (1999) 19:11017–11026.
   Google Scholar
• KAPLAN GB, SEARS MT: Adenosine receptor agonists attenuate and adenosine receptor antagonists exacer-bate opiate withdrawal signs. Psychopharmacology (1996) 123:64–70.
   Google Scholar
• GREENGARD P, NAIM AC, GIRAULT JA et al.: The DARPP-32 /protein phosphatase-1 cascade: a model for signal integration. Brain Res. Brain Res. Rev. (1998) 26:274–284.
   Google Scholar
• PORKKA-HEISKANEN T: Adenosine in sleep and wakefulness. Ann. Med. (1999) 31:125–129
   PubMed Web of Science ®Google Scholar
• SCHWIERIN B, BORBELY AA, TOBLER I: Effects of N6-cyclopentyladenosine and caffeine on sleep regula-tion in the rat. Eur. j Pharmacol. (1996) 300:163–171.
   Google Scholar
• MENDELSON W: Sleep-inducing effects of adenosine microinjections into the medial preoptic area are blocked by flumazenil. Brain Res. (2000) 852:479–481.
   Google Scholar
• DUNWIDDIE TV, FREDHOLM BB: Adenosine A1 receptors inhibit adenylate cyclase activity and neurotrasmitter release and hyperpolarize pyramidal neurons in rat hippocampus. J. Pharmacol. Exp. Ther. (1989) 249:31–37.
   PubMed Web of Science ®Google Scholar
• FIEBICH BL, BIBER K, LIEB K et al.: Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2A-receptor. Glia (1996) 18:152–160.
   PubMed Web of Science ®Google Scholar
• MONOPOLI A, LOZZA G, FORLANI A, MATTAVELLI A, ONGINI E: Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. NeuroReport (1998) 9:3955–3959.
   PubMed Web of Science ®Google Scholar
• STONE TW, BEHAN WMH: Adenosine receptors, kynurenines and neuroprotection. Drug Dev. Res. (2000) 50:15.
   Google Scholar
• POPOLI P, PEZZOLA A, REGGIO R, MALCHIODI AF, FALCHI M: Adenosine A2A receptor blockade prevents IIG and motor abnormalities in a rat model of Huntington's disease. Drug Dev. Res. (2000) 50:69.
   Google Scholar
• CHEN JF STAAL R, XU K, BEILSTEIN M, SONSALLA PK, SCHWARZSCHILD TH: Novel neuroprotection by adenosine A2A receptor inactivation in an animal model of Parkinson's disease. Drug Dev. Res. (2000) 50:71.
   Google Scholar
• LIBERATORE GT, JACKSON-LEWIS V, VUKOSAVIC S et al.: Inducible nitric oxide synthase stimulates dopamin-ergicneurodegeneration in the MPTP model of Parkin-son's disease. Nature Med. (1999) 5:1403–1409.
   PubMed Web of Science ®Google Scholar
• HIRSH EC, HUNOT S: Nitric oxide, glial cells and neuronal degeneration in parkinsonism. Trends Pharmacol. ScL (2000) 21:163–165
   Google Scholar
• ABBRACCHIO MP, CATTABENI F: Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative disease. Ann. NY Acad. ScL (1999) 890:79–92.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of the mechanisms and thereceptor subtypes involved in adenosine-mediated neuroprotection.
   Google Scholar
• GUIDETTI P, REDDY PH, TAGLE DA, SCHWAREZ R: Early kynurenergic impairment in Huntington's disease and in transgenic animal model. Neurosci. Lett. (2000) 283:233–235.
   PubMed Web of Science ®Google Scholar
• MCDONALD C, MURRAY RM: Early and late environ-mental risk factors for schizophrenia. Brain Res. Brain Res. Rev. (2000) 31:130–137.
   PubMed Web of Science ®Google Scholar
• IMPAGNATIELLO F, GUIDOTTI AR, PESOLD C et al: A decrease of reelin expression as a putative vulner-ability factor in schizophrenia. Proc. Nati Acad. Sci. USA (1998) 95:15718–15723
   PubMed Web of Science ®Google Scholar
• BARONDES SH, ALBERTS BM, ANDREASEN NC et al: Workshop on schizophrenia. Proc. Nati Acad. Sci. USA (1997) 94:1612–1614.
   PubMed Web of Science ®Google Scholar
• •Expert opinion on schizophrenia research.
   Google Scholar
• KYOSSEVA SV, ELBEIN AD, GRIFFIN WS, MRAK RE, LYON M, KARSON CN: Mitogen-activated protein kinases in schizophrenia. Biol. Psychiatry (1999) 46:689–696.
   PubMed Web of Science ®Google Scholar
• YAN Z, HSICH-WILSON L, FENG J et al.: Protein phosphatase 1 modulation of neostriatal AMPA channels: regulation by DARPP-32 and spinophilin. Nature Neurosci. (1999) 2:13–17.
   PubMed Web of Science ®Google Scholar
• IKEMOTO S, PANKSEPP J: The role of nucleus accumbens dopamine in motivated behaviour: a unifying interpretation with special reference to reward-seeking. Brain Res. Brain Res. Rev. (1999) 31:6–41.
   PubMed Web of Science ®Google Scholar
• RIVKEES SA, REPPERT SM: RFL9 encodes an A2b-adenosine receptor. Mol. Endocrinol. (1992) 6:1598–1604.
   PubMed Web of Science ®Google Scholar
• PIERCE KD, FURLONG TJ, SELBIE LA, SHINE J: Molecular cloning and expression of an adenosine A2b receptor from human brain. Biochem. Biophys. Res. Commun. (1992) 187:86–93.
   PubMedGoogle Scholar
• MARQUART DL, WALKER LL, HEINEMANN S: Cloning of two adenosine receptor subtypes from mouse bone marrow-derived mast cells. J. Immunol. (1994) 152:4508–4515.
   Google Scholar
• JACOBSON MA, JOHNSON RG, LUNEAU CJ, SALVATORE CA: Cloning and chromosomal localization of the human A2b adenosine receptor gene (ADORA2B) and its pseudogene. Genomics (1995) 27:374–376.
   Google Scholar
• PUFFINBARGER NK, HANSEN KR, RESTA R et al.: Produc-tions and characterization of multiple antigenic peptide antibodies to the adenosine A2b receptor. Mol. Pharmacol. (1995) 47:1126–1132.
   Google Scholar
• PALMER TM, STILES GL: Structure-function analysis of inhibitory adenosine receptor regulation. Neurophar-macology (1997) 36:1141–1141.
   PubMed Web of Science ®Google Scholar
• STEHLE JH, RIVKEES SA, LEE JJ, WEAVER DR, DEEDS JD, REPPERT SM: Molecular cloning and expression of the cDNA for a novel A2-adenosine receptor subtype. Mol. Endocrinol. (1992) 6:384–393.
   PubMed Web of Science ®Google Scholar
• MOGUL DJ, ADAMS ME, FOX AP: Differential activation of adenosine receptors decreases N-type but potenti-ates P-type Ca2+ current in hippocampal CA3 neurons. Neuron (1993) 10:327–334.
   Google Scholar
• KESSEY K, TROMMER BL, OVERSTREET LS, JI T, MOGUL DJ: A role for adenosine A2 receptors in the induction of long-term potentiation in the CA1 region of rat hippocampus. Brain Res. (1997) 756:184–190.
   PubMed Web of Science ®Google Scholar
• PEAKMAN MC, HILL SJ: Adenosine A2B-receptor--mediated cyclic AMP accumulation in primary rat astrocytes. Br. J. Pharmacol (1994) 111:191–198.
   PubMed Web of Science ®Google Scholar
• YAKEL JL, WARREN RA, REPPERT SM, NORTH RA: Functional expression of adenosine A213 receptor in Xenopus oocytes. Mol. Pharmacol (1993) 43:277–280.
   Google Scholar
• FEOKTISTOV I, BIAGGIONI I: Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J. Clin. Invest. (1995) 96:1979–1986.
   PubMed Web of Science ®Google Scholar
• PHILLIS JW, SMITH-BARBOUR M, PERKINS LM, O'REGAN MH: Acetylcholine output from the ischemic rat cerebral cortex: effects of adenosine agonists. Brain Res. (1993) 613:337–340
   PubMed Web of Science ®Google Scholar
• PHILLIS JW, O'REGAN MH, PERKINS LM: Effect of adenosine receptor agonists on spontaneous and K(+)-evoked acetylcholine release from the in vivo rat cerebral cortex. Brain Res. (1993) 605:293–297.
   Google Scholar
• OKADA M, MIZUNO K, KANEKO S: Adenosine Ai and A2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci. Lett. (1996) 21:53–56.
   Google Scholar
• FORSYTHE P, ENNIS M: Adenosine, mast cells and asthma. Inflamm. Res. (1999) 48:301–307.
   PubMed Web of Science ®Google Scholar
• FEOKISTOV I, POLOSA R, HOLGATE ST, BAGGIONI I: Adenosine A213 receptors: a novel therapeutic target in asthma? Trends Pharmacol. Sci. (1998) 19:148–153.
   Google Scholar
• MEYERHOF W, MULLER-BRECHLIN R, RICHTER D: Molecular cloning of a novel putative G-protein coupled receptor expressed during rat spermio-genesis. FEBS Lett. (1991) 284:155–160.
   PubMed Web of Science ®Google Scholar
• LINDEN J, TAYLOR HE, ROBEVA AS et al. Molecular cloning and functional expression of a sheep A3 adenosine receptorwith widespread tissue distribu-tion. Mol. Pharmacol. (1993) 44:524–532.
   PubMed Web of Science ®Google Scholar
• SAJJADI FG, BOYLE DL, DOMINGO RC, FIRESTEIN GS: cDNA cloning and characterization of A3, an alterna-tively spliced rat A3 adenosine receptor variant. FEBS Lett. (1996) 382:125–129.
   PubMed Web of Science ®Google Scholar
• PALMER TM, BENOVIC JL, STILES GL: Molecular basis for subtype-specific desentization of inhibitory adenosine receptors. Analysis of chimeric A1-A3 adenosine receptor. J Biol. Chem. (1996) 271:15272–15278.
   PubMed Web of Science ®Google Scholar
• DE M, AUSTIN KF, DUDLEY MW: Differential distribu-tion of A3 receptor in rat brain. Soc. Neurosci. Abstr. (1993) 19:42.11.
   Google Scholar
• JACOBSON KA, NIKODIJEVIC O, SHI D, GALLO-RODRIGUEZ C, OLAH ME, STILES GL, DALY JW: Arole for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. (1993) 336:57–60.
   PubMed Web of Science ®Google Scholar
• RIVKEES SA, THEVANANTHER S, HAO H: Are A3 adenosine receptor expressed in the brain? NeuroRe-port (2000) 11:1025–1030.
   Google Scholar
• ZHOU QY, LI C, OLAH ME, JOHNSON RA, STILES GL, CIVELLI O: Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc. Nati Acad. Sci. USA (1992) 89:7432–7436.
   PubMed Web of Science ®Google Scholar
• ABBRACCHIO MP, BRAMBILLA R, CERUTI S et al: G-protein-dependent activation of phospholipase Cby A3 adenosine receptors in rat brain. Mol. Pharmacol. (1995) 48:1038–1045.
   PubMed Web of Science ®Google Scholar
• BARAUDI PG, CACCIARI B, ROMAGNOLI R et al: A3 adenosine receptor ligands: history and perspectives. Med. Res. Rev. (2000) 20:103–128.
   Google Scholar
• VON LUBITZ DK, LIN RC, POPIK P, CARTER MF, JACOBSON KA: Adenosine A3 receptor stimulation and cerebral ischemia. Eur.J. Pharmacol. (1994) 263:59–67.
   PubMed Web of Science ®Google Scholar
• DUNWIDDIE TV, DIA0 L, KIM HO, JIANG JL, JACOBSON KA: Activation of hippocamp al adenosine A3 receptors produces a desensitization of Ai receptor-mediated responses in rat hippocampus. j Neurosci. (1997) 17 :607–614.
   PubMed Web of Science ®Google Scholar
• JACOBSON KA, PARK KS, JIANG JL et al.: Pharma-cological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology (1997) 36:1157–1165.
   PubMed Web of Science ®Google Scholar